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heart, microRNA-499c, promotes myofibril
formation and rescues cardiac development in
mutant axolotl embryos
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Background: A recessive mutation “c” in the Mexican axolotl, Ambystoma mexicanum, results in the failure of
normal heart development. In homozygous recessive embryos, the hearts do not have organized myofibrils and fail
to beat. In our previous studies, we identified a noncoding Myofibril-Inducing RNA (MIR) from axolotls which
promotes myofibril formation and rescues heart development.
Results: We randomly cloned RNAs from fetal human heart. RNA from clone #291 promoted myofibril formation
and induced heart development of mutant axolotls in organ culture. This RNA induced expression of cardiac
markers in mutant hearts: tropomyosin, troponin and α-syntrophin. This cloned RNA matches in partial sequence
alignment to human microRNA-499a and b, although it differs in length. We have concluded that this cloned RNA
is unique in its length, but is still related to the microRNA-499 family. We have named this unique RNA, microRNA-
499c. Thus, we will refer to this RNA derived from clone #291 as microRNA-499c throughout the rest of the paper.
Conclusions: This new form, microRNA-499c, plays an important role in cardiac development.
Keywords: Myofibrillogenesis, Tropomyosin, Cardiac mutant axolotl, Human embryonic heart RNA, microRNABackground
The Mexican axolotl, Ambystoma mexicanum, is an ex-
citing and useful animal model to study vertebrate heart
development and cardiac myofibrillogenesis. It carries a
lethal cardiac recessive mutation, designated by gene “c”,
which, when homozygous (c/c), prevents normal heart
development in axolotl embryos. Our previous studies
[1] have shown that a non-coding RNA, Myofibril-
Inducing RNA (MIR) from normal axolotl, is capable of
promoting myofibrillogenesis and beating hearts in the
mutant (c/c) axolotl embryos. This study demonstrated
that the MIR gene is essential for tropomyosin expres-
sion in axolotl hearts during development. Real-Time
PCR studies showed that mRNA expression of various
tropomyosin isoforms in untreated mutant hearts is
similar to normal hearts knocked down with double-* Correspondence: Andrei.Kochegarov@tamuc.edu
Department of Biological and Environmental Sciences, Texas A&M University-
Commerce, P.O. Box 3011, Commerce, TX 75429-3011, USA
© 2013 Kochegarov et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumstranded MIR (dsMIR). These results suggest that MIR
is involved in controlling expression of various tropomy-
osin isoforms and subsequently in regulating cardiac
contractility. The MIR was sequenced and found to be
166 nucleotides in length [2]. This RNA is unique in that
it does not show significant homology to any known
sequences in the online NCBI database. Comparison
between MIR sequences obtained from normal and
mutant embryos demonstrated a single point mutation
at base 93 of the mutant MIR nucleotide sequence [2].
Genebee (Moscow State University), an online bioinfor-
matics tool for the computation and modeling of sec-
ondary structures of RNAs, showed a conformational
difference between the normal bioactive MIR and the
mutant MIR, suggesting that the secondary structure
of MIR might be important in the mutant rescue
process [2]. More recently we have found that total hu-
man fetal heart RNA also has the ability to promote
normal myofibril formation and restore function of thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Primers used for genes in real time RT-PCR
experiments
Gene of interest Forward/ Reverse Primer
Tropomyosin Forward 50-ggagcttgaccatgcgctgaa
Tropomyosin Reverse 50-tgagaaccgacacaaagcaagagg
troponin T Forward 50-ccaagggcttcaccgggctcaa
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homologue of the axolotl MIR could be present in
human fetal heart tissue [3]. In the present study,
through the random cloning of genes expressed in human
heart, we have found a clone with the capacity to produce
RNAs with the capability of promoting myofibrillogenesis
and rescuing cardiac mutant axolotl hearts similarly to
the axolotl MIR. We have designated this clone as a
microRNA-499c. The role of microRNA-499 in heart
development in human cardiomyocyte differentiation
was previously described [4,5]. Our identification of the
human microRNA which promotes myofibrillogenesis
helps us to understand the molecular mechanism of
heart development and may have important implica-
tions for future treatment of myocardial infarcts, cardio-




For cloning, a total of 2 μg of human fetal heart RNA
(Agilent Technologies, Inc #540165) was used for each
reaction. The cloning kit used was the CloneMiner™ II
cDNA Library Construction Kit (Invitrogen, #A11180).
First and second DNA strands were synthesized from
template RNAs and ligated into the pDONR222 vector.
The pDONR222 vector contains the kanamycin resist-
ance gene which allows selection of transfected bacteria
and the ccdB gene which interferes with E. coli DNA
gyrase allowing negative selection of the donor vector
in E. coli following recombination and transformation.
The ElectroMAX™ DH10B™ T1 Phage Resistant E. coli
strain provided with the kit was transformed using the
EC 1000 Electroporator (Thermo ES) at 2800 V. To
each sterile cuvette, 50 μl ElectroMAX™ DH10B cells,
1.5 μl of (150 ng/μl) vector and 50 μl of dH2O were
added. In case the sample arced at this voltage setting,
100 μl of dH2O, or more, was added to increase elec-
trical resistance. After electroporation, the cells were
added to 1 ml of S.O.C. medium and cultured in 15 ml
snap-cap tubes for at least 1 hour at 37°C on a shaker
at 225–250 rpm to allow expression of the kanamycin
resistance marker. Serial dilutions of sample aliquots
with S.O.C. medium at the ratios 1:10, 1:100 and 1:1000
were plated on LB agar plates containing 50ug/ml of
kanamycin. The remaining cells were frozen at -80°C.
Plated cells were incubated overnight at 37°C. Individ-
ual colonies were collected and transferred into snap-
cap tubes with 2 ml of 2xYT medium containing
50ug/ml of kanamycin and incubated overnight. Plas-
mids with clones were extracted according to the
standard Miniprep Plasmid DNA Isolation Protocol
found in the online archive of the Institute of Bio-
informatics and Applied Biotechnology.BsrGI digestion
Extracted plasmids (5 μl sample) were digested by 20U
(1U/μl) of enzyme BsrGI in 1X NE Buffer with 0.1 mg/μl
of BSA. The mixtures were incubated for 1 h at 37°C
and analyzed by Gel electrophoresis on 1% agarose gels
containing 0.5 μg/ml of ethidium bromide.
PCR
T7 RNA polymerase binding site TAATACGACTCACTA






PCR was performed using a MyTaq™ Red Mix kit
(Bioline, BIO-25043) according to the instruction man-
ual for this kit: denaturation at 95°C during 15 sec
followed by annealing at 55°C for 15 sec and elongation
at 72°C for 15 sec for 30 cycles. The resulting DNA was
purified by 5 M sodium chloride salt and isopropanol
precipitation. Pellets were washed with 70% ethanol and
re-suspended in 1X Tris-EDTA buffer.
RNA synthesis
The transcription reaction mixture was assembled from
the MAXIscriptW T7 Kit, Ambion # AM1314M. Then,
we added 1 μg of DNA from the PCR product, 2 μL
of 10X transcription buffer, 2 μL of T7 Enzyme Mix
and 1 μL of each (10 mM) NTP; and adjusted the vol-
ume to 20 μL by nuclease-free water. The reaction mix-
ture was incubated at 37°C for 2 hours. RNA was
purified using ammonium acetate and ethanol precipita-
tion and resuspended in nuclease-free water. The con-
centration of RNA was determined spectrophotometrycally
at 260 nm.using a Synergy HT (Bio-Tek) platereader.
Bioassay
Cardiac mutant non-function carrier (+/c) adult axolotls
were obtained from the Ambystoma Genetic Stock
Figure 1 Successful cloning of human RNAs. Gel electrophoresis
of (A) individual plasmid digestion fragments with BsrGI. A uniform
2.5 kb band represents the unchangeable vector portion, and
variable bands are different size cloned RNAs. (B) Gel electrophoresis
of cloned DNAs from PCR. (C) Gel electrophoresis of cloned RNAs
from reverse transcription reaction.
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erozygous adult animals were mated (+/c x +/c) to
produce mutant (c/c) and wildtype (+/+) embryos for
our studies. Embryos were collected and allowed to
develop to heart-beat stages 35-36, according to the
Bordzilovskaya et al. staging system [6]. For bioassays,
only double recessive mutant c/c embryos were se-
lected which do not have beating hearts. The embryosFigure 2 Tropomysin expression in RNA-treated mutant axolotl heart
microscopy. (A) Normal heart. (B) Mutant untreated heart. (C) Mutant hea
organ culture. Magnification is the same in all images.were anaesthetized by 0.7 mg/ml tricaine methanesulfonate
or Ms-222 (Argeitt Chemicals Labs) in Holtfreter’s solution
[7]. Embryos were dissected under a binocular microscope
in clay-lined Petri dishes in Holtfreter’s medium containing
1% antibiotic/antimycotic (Gibco #15240). Hearts were
transferred into the Petri dishes on Parafilm substrate into
50 μl of Holtfreter’s solution (without antibiotic) containing
7 ng/μl of human fetal heart RNA from individual clones
along with 0.1 mg/ml of lipofectamine. reagent (Invitrogen,
Carlsbad CA). The Petri dishes with hearts were enclosed
in a plastic container containing wet paper towels to
maintain a saturated humidity environment at 17°C.
Fixation and staining procedure
All steps were performed at room temperature as previ-
ously described [2]. Hearts were fixed in 4% paraformal-
dehyde for 30 min and rinsed twice in PBS for 3 min.
Hearts were permeabilized in 0.05% Tween-20 and 3%
BSA in PBS for 1 h. Hearts were incubated overnight
with monoclonal anti-tropomyosin CG3 antibody (Devel-
opmental Studies Hybridoma Bank, University of Iowa)
diluted to 1:75 in PBS, and then washed several times
in PBS. Hearts were incubated in goat anti-mouse poly-
clonal secondary antibody (Abcam, # ab6669) at a 1:75
dilution for 1 h. The hearts were rinsed in several
changes of PBS and mounted on slides in SlowFadeW
Gold antifade reagent (Invitrogen, #S36936). Three
layers of fingernail polish were applied to the edges of
glass coverslips to prevent damaging of the whole
hearts. Antibodies conjugated with FITC were excited
at 488 nm with an emission at 520 nm. The stained
heart samples were scanned under a laser confocal
microscope, Olympus Fluoview, equipped with a com-
puter to record the images.
qRT-PCR
Normal and mutant embryonic hearts at stage 36-37
were placed into 15 μl droplet cultures of Holtfreter’s
solution containing antibiotics [1]. Mutant hearts weres revealed by immunofluorescent staining with confocal
rt treated with cloned RNA (clone #291) after 5 days of incubation in
Figure 3 (A) DNA sequence of cloned RNA from the clone #291 (microRNA-499c). Underlined area is 22 bp microRNA-499. (B) Alignment of
cloned RNA with microRNA-499 generated in Mirbase [8].
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from clone #291 and incubated at 14°C for 72 hours.
Each treatment group consisted of 10 hearts. RNA was
extracted using a NucleoSpin RNAII Kit (Macherey-nagel)
from ten mutant hearts treated with the active clone
of human RNA (microRNA-499c), from 10 untreated
(treated only with lipofectin) hearts as a control, and
from ten normal hearts. qRT-PCR was performed with
a Rotor-Gene machine using a Rotor-Gene SYBR PCR
kit (Qiagen #204074) with primers as reported in
Table 1 [1]. Expression in normal heart was considered
as 100%. Expression was normalized (divided) by β-
actin expression.
Results and discussion
On the basis of our results we hypothesize that normal
human fetal heart expresses an RNA, which is a func-
tional homologue to the axolotl MIR, and which prob-
ably is required for human heart development and
function. Our results have clearly shown that if we clone
this RNA from human fetal heart and transfect it into
mutant axolotl hearts, normal heart development is re-
stored. In an earlier publication, our laboratory showed
that RNA extracted from human fetal and adult hearts,
but not from skeletal muscle, rescued the development
of mutant axolotl hearts in organ culture [3]. These
earlier experiments suggest that total human heart
RNAs, but not skeletal muscle, contain functionalFigure 4 Alignment of cloned RNA (microRNA-499c) with (A) microRNhomologues of the MIR (myofibril-inducing RNA) de-
rived from normal embryonic axolotl anterior endo-
derm [1].
A cDNA library was generated from total RNA extracted
from human fetal heart that was purchased from Agilent
Technologies Inc (Santa Clara, CA). We randomly
cloned 400 individual RNAs from human fetal heart
using the pDONR222 plasmid as a vector. DNA clones
were synthesized by PCR using the vectors as templates
and M13 primers. The PCR products were visualized
through agarose gel electrophoresis and ethidium bromide
staining. A vast majority of clones showed unique DNA
bands (Figure 1B) indicating the presence of specific DNA
inserts in the plasmids (Figure 1B). The RNAs were
synthesized by using an in vitro transcription reaction
and run on an agarose gel to test the result of the reac-
tion (Figure 1C). RNA clones along with 0.1 mg/ml of
lipofectamine transfection reagent were diluted to a
concentration of 7 ng/μl in Holtfreter’s solution containing
a physiological mixture of salts required for cardiomyocyte
contraction. The hearts were incubated in a plastic con-
tainer at saturated humidity and room temperature. Each
individual clone was tested on three hearts.
Transfection with RNA derived from clone #291 was
found to induce mutant hearts to beat. Initially, the
treated hearts beat sporadically. However, with additional
time in organ culture, the beating became more vigorous
and regular. Hearts were fixed in paraformaldehyde andA-499a and (B) microRNA-499b.
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Confocal microscopy revealed significant expression of
tropomyosin in hearts treated with RNA derived from
clone #291 (Figure 2C). Mutant axolotl hearts, which
were not treated with any RNA or with RNA derived
from non-active clones, do not show tropomyosin ex-
pression and beating (Figure 2B).
The sequence analysis revealed a 111 bp long sequence
of the cloned RNA (Figure 3A). We screened the sequence
in Mirbase [8] and found that 22 bp microRNA-499 frag-
ment is included in the cloned sequence (Figure 3B).
Screening of the human genome database with the Basic
Local Alignment Search Tool software (BLAST), on the
NCBI website showed that the cloned sequence fromFigure 5 Time-course study of the relative quantities of tropomyosin
(7 ng/μl of microRNA499c) axolotl hearts. A. The immunofluorescent im
after incubation with 7 ng/μl of microRNA499c for 0, 1, 2, 3, 4 and 5 days;
fluorescence were quantified with ImageJ software as a percentage of that ex
between treated on the second day following days hearts and untreated heaclone #291 is identical to an intron of one of the my-
osin heavy chain (MHC) genes. Also we screened the
online microRNA database, Mirbase [8], and we found
homology with a 22 bp miR-499 fragment included in
the cloned sequence (Figure 3B). There are two known
forms of the microRNA-499 precursor: microRNA-
499a and microRNA-499b. Alignment of the cloned
RNA, microRNA-499c, with precursors microRNA-
499a and microRNA-499b showed that although they
differ in size, they have common and overlapping se-
quences (Figure 4B). Precursors of the microRNA,
microRNA-499a has 122 bp, while microRNA-499b has
only 73 bp and the newly discovered form, microRNA-
499c has 111 bp. Alignment showed that a new formexpression by immunofluorescence staining in RNA-treated
ages show mutant hearts that were fixed and stained for tropomyosin
the 0- control was without treatment. B. The average levels of
pressed in normal hearts, which was set to 100%. Significance (*p-value)
rts is p < 0.05, n=3.
Figure 6 Relative expression of cardiac markers by RT-PCR in
mutant hearts (c/c), mutant hearts transfected with the microRNA-
499c (c/c RNA) and normal hearts (+/+): (A) tropomyosin,
(B) cardiac Troponin T and (C) α-syntrophin. Expression was
calculated as percentage of that expressed in normal hearts
(expression in normal hearts was assumed as 100%). Significance
between treated and untreated mutant hearts is for tropomyosin,
p < 0.05, cardiac Troponin T p < 0.02 and α-syntrophin p < 0.03, n=10.
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499a and 66 common bp with microRNA-499b. Thus,
we conclude that we have discovered a new form of
microRNA-499 precursor, which we term microRNA-499c.
Time-course experiment
The hearts from mutant axolotl embryos were incubated
with the microRNA-499c during different periods of
time: 1, 2, 3, 4 and 5 days. Embryos at the time of dissec-
tion were at post-heart-beat stage 36-37. After incuba-
tion with RNA, the hearts were fixed and stained with
anti-tropomyosin antibodies (Figure 5A). Fluorecsence
levels of heart images were quantified with ImageJ soft-
ware (National Institutes of Health) (Figure 5B). At the
initial point, (0 days) the heart does not show tropomy-
osin expression. During the 4 days of incubation, tropo-
myosin expression gradually increases. Starting with day
2 and following days, significance between treated hearts
and untreated hearts is less than 0.05 (p < 0.05, n=3).
Also, during the time increment of incubation, the
numbers of striated myofibrils increases. Striated
myofibrils are prominent by the 5th day of RNA treatment
of mutant hearts in organ culture, as well as in normal
hearts (Figure 2A and C).
qRT-PCR
RNA was extracted from ten mutant hearts treated with
the active clone of RNA (7 ng/μl of microRNA-499c),
from 10 untreated (treated only with lipofectin) mutant
hearts as a control, and from ten normal hearts. Expres-
sion of genes considered as cardiac markers included:
tropomyosin, cardiac troponin T and α-syntrophin all
of which increased significantly in comparison to β-
actin in the RNA-treated hearts (Figure 6). Expression
was calculated as % of expression relative to normal
hearts, which was assumed to be 100%. In mutant hearts,
expression of cardiac markers was much lower than in
normal heart, as low as 10-20%. After treatment with the
active clone of RNA (7 ng/μl of microRNA499c), expres-
sion in mutant hearts increased significantly up to 70-90%:
tropomyosin – 75%, cardiac Troponin T – 70% and α-
syntrophin – 90%. Tropomyosin is an important protein
in sarcomere formation and in muscle contraction [9].
Troponin is required to regulate Ca(2+)-dependent con-
tractions, and it was shown to be essential for sarcomere
assembly in cardiac and skeletal muscles. The increased
expression of these mRNAs suggests that the rescue of
mutant hearts has taken place, when the muscle myofila-
ments start to be expressed and assemble into functional
sarcomeric myofibrils. The increased expression of cardiac
markers is consistent with data from our previous pub-
lication [1]. In that publication, expression of multiple
cardiac makers: cardiac Troponin T, α-syntropin and
tropomyosin increased after 36 and 72 hours incubationwith Myofibril-Inducing RNA (MIR) from axolotl. In
the current experiment, this active clone of RNA from
human heart (microRNA-499c) also increased expression
of cardiac troponin T, α-syntropin and tropomyosin.
Our results show that RNA cloned from human fetal
heart has the capability of rescuing mutant axolotl hearts
in organ culture bioassays. The rescue of mutant hearts
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hearts and expression of tropomyosin in organized
myofibrils after incubation with the microRNA-499c.
All three microRNA-499 precursors apparently originate
from the same intron, which is initially the intron of the
myosin heavy chain (MHC) genes.
The human microRNA-499 belongs to a family of
micro RNAs encoded by the intron of the myosin heavy
chain (MHC) genes, referred to as MyomiRs which also
include microRNA-208a and microRNA-208b. MicroRNA-
499 is highly conserved, being present in the genome of
many vertebrate species (human, mouse, rat, bovine,
Xenopus and zebrafish) [10]. Micro-RNAs are non-
coding RNAs which regulate the translation of genes by
binding to untranslated sites (UTRs) in their targets.
Nascent precursor microRNAs are usually about one
hundred or more nucleotides long, and later, microRNAs
are split by enzymes into a short active 22 bp fragment.
In animals, expression of microRNAs occurs in two
stages. First, in the nucleus, pre-microRNAs are cleaved
from an extended primary transcript of the gene which
then is exported to the cytoplasm of the cell. In the cell
cytoplasm, endoribonuclease, called Dicer, cleaves the
double-stranded RNA (dsRNA) into a short 22 nucleo-
tide micro-RNA. The mature microRNA is incorporated
into the RNA-induced silencing complex (RISC) which
includes Dicer and other proteins. The miRNA binds
complementary mRNAs and directs them to degradation
by endonucleases or prevent their translation by holding
them in the RISC. In situ hybridization analysis of mouse
heart, brain, spleen, liver, lung, quadriceps muscle, kidney,
and gut tissues shows that the mature microRNA-499 is
abundantly expressed in cardiac tissue and almost absent
in other tissues, including skeletal muscle [10]. Some of
those predicted targets of microRNA-499 and microRNA-
1 were shown to regulate cardiomyocyte differentiation.
Transient transfection of microRNA-1 and -499 in human
cardiomyocyte progenitor cells (CMPCs) reduced the
proliferation rate and increased differentiation into
cardiomyocytes. This effect most likely occurs by re-
pression of histone deacetylase 4 or Sox6 because levels
of these proteins are reduced [10]. It has been found
that microRNA-499 promotes ventricular specification
in differentiating human embryonic stem cells [11]. It
was shown further that microRNA-499 expression
increased in human stem cells differentiating into
cardiomyocytes. Also, microRNA-499 transduction
by the lentivirus of hESC-derived cardiovascular progeni-
tors significantly increased the yield of stem cell-derived
ventricular specified cardiomyocytes [11]. Other results
suggest that expression of microRNA-499 in human car-
diac stem cells (hCSCs) represses the microRNA-499 tar-
get genes Sox6 and Rod1, enhancing cardiomyogenesis
in vitro and after infarction in vivo [5]. The level ofmicroRNA-499 was 400 times higher in cardiomyocytes
than in rat cortical stem cells. Cardiomyocytes derived
from differentiation of hCSCs treated with microRNA-499
appeared to be larger, and their sarcomere striations
were more evident [5]. Expression of microRNA-499
was observed to be increased a few hundred times dur-
ing differentiation of human embryonic stem cells into
beating clusters [4]. Also, overexpression of microRNA-
499 enhanced expression of myocyte-specific enhancer
factor 2C, the transcription factor which is involved in
cardiac morphogenesis and myogenesis and vascular
development [4]. Thus, microRNA-499 appears to play
an important role during heart development, although
the molecular mechanisms and the microRNA-499
pathways are not well understood at this time.
Conclusion
Our results demonstrate clearly and unequivocally that
human-derived microRNA-499c promotes the formation
of cardiac myofibrils in cells of cardiac mutant sala-
mander hearts and thus restores normal embryonic heart
development in these lower vertebrate species. This obser-
vation is consistent with earlier publications showing that
microRNA-499 plays an important role in cardiac dif-
ferentiation and cardiogenesis during embryonic develop-
ment, and it strongly suggests a ubiquitous and conserved
mechanism of classic embryonic heart induction [12,13] and
myofibrillogenesis across the spectrum of vertebrate species.
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